Dawson James initiated coverage on Bluejay Diagnostics with a new price target
$BJDX
Medical/Dental Instruments
Health Care
Dawson James initiated coverage of Bluejay Diagnostics with a rating of Buy and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2022 | $10.00 | Buy | Dawson James |
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
3 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)
SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)
SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update. Recent Business Highlights and Developments: SYMON Clinical Program Update: The Company has initiated its pivotal SYMON-II clinical study, following the successful completion of the SYMON-I pilot study, for which a primary analysis highlighted that IL-6 levels within 24 hours of ICU admission may predict sepsis patient mortality out to 28 days. Currently, the Company is collecting, freezing and biobanking samples, w
ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company's lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 (IL-6) in sepsis patients intended or admitted for the intensive care unit (ICU), will be presented. SYMON-I evaluated IL-6 as a prognosticator for 28-day mortality and exploratory endpoints including 7-day mortality and microbiological positivity. "Early use of IL-6 in sepsis and septic shock pat
ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase up 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share, resulting in gross proceeds of approximately $3.7 million, before deducting
Dawson James initiated coverage of Bluejay Diagnostics with a rating of Buy and set a new price target of $10.00
8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
DEF 14A - Bluejay Diagnostics, Inc. (0001704287) (Filer)
10-Q - Bluejay Diagnostics, Inc. (0001704287) (Filer)
ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company") a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin "Ed" E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report to Neil Dey, Chief Executive Officer. Mr. Rule is a highly credentialed regulatory, quality and compliance professional with more than 15 years of industry experience. He has extensive training and expertise in medical device regulations in the U.S. and numerous international markets.
ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay") a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay's clinical development programs and provide strategic medical and scientific leadership to the Company. "I am very pleased to welcome Mark on board as Chief Medical Advisor. I believe Mark's expansive clinical background and strategic leadership skills will be invaluable as we seek to develop the Compa